Perspective
Split Viewer
Korean J Hematol 2010; 45(3):
Published online September 30, 2010
https://doi.org/10.5045/kjh.2010.45.3.145
© The Korean Society of Hematology
Freedom to choose a cure: how safe is a deadly cancer?
Department of Pathology and Diagnostic, University of Verona Medical School, Verona, Italy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Rosa, DD, Harris, J, Jayson, GC. The best guess approach to phase I trial design. J Clin Oncol, 2006;24;206-208.
- Agrawal, M, Grady, C, Fairclough, DL, Meropol, NJ, Maynard, K, Emanuel, EJ. Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol, 2006;24;4479-4484.
- Thomas, LG. Regulation and firm size: FDA impacts on innovation. Rand J Econ, 1990;21;497-517.
- Senderowicz, AM. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. Clin Cancer Res, 2010;16;1719-1725.
- Friedman M, Friedman R. Free to Choose: a personal statement. New York, USA: Harcourt Brace Jovanovich.
PDF
Standard view
Export citation
Share Article
Perspective
Korean J Hematol 2010; 45(3): 145-146
Published online September 30, 2010 https://doi.org/10.5045/kjh.2010.45.3.145
Copyright © The Korean Society of Hematology.
Freedom to choose a cure: how safe is a deadly cancer?
Vladia Monsurró, Ph.D.
Department of Pathology and Diagnostic, University of Verona Medical School, Verona, Italy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Rosa, DD, Harris, J, Jayson, GC. The best guess approach to phase I trial design. J Clin Oncol, 2006;24;206-208.
- Agrawal, M, Grady, C, Fairclough, DL, Meropol, NJ, Maynard, K, Emanuel, EJ. Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol, 2006;24;4479-4484.
- Thomas, LG. Regulation and firm size: FDA impacts on innovation. Rand J Econ, 1990;21;497-517.
- Senderowicz, AM. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. Clin Cancer Res, 2010;16;1719-1725.
- Friedman M, Friedman R. Free to Choose: a personal statement. New York, USA: Harcourt Brace Jovanovich.
Previous Article
